A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF KRN23 VERSUS ORAL PHOSPHATE AND ACTIVE VITAMIN D TREATMENT IN PEDIATRIC PATIENTS WITH X LINKED HYPOPHOSPHATEMIA (XLH)
- Registry ID
- UX023-CL301
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ULTRAGENYX PHARMACEUTICAL INC
- Start date
- 2018-05-25
- Last update
- 2016-06-17
Conditions
- X-LINKED HYPOPHOSPHATEMIA
View on source registry